Potential Milestone Year Ahead For Korean NASH Contenders
Hanmi Leads With US Phase II Trials
Scrip takes a look at key recent drug development activities in the NASH area by Korean firms, which are now pursuing the global development of their candidates as they look to leverage innovation to expand internationally.
